References
- Belkaid Y, Hand TW. (2014). Role of the microbiota in immunity and inflammation. Cell, 157(1), 121–141.
- Belkaid Y, Harrison OJ. (2017). Homeostatic immunity and the microbiota. Immunity, 46(4), 562–576.
- De la Fuente M, Miquel J. (2009). An update of the oxidation-inflammation theory of aging: the involvement of the immune system in oxi-inflamm-aging. Curr Pharm Des, 15(26), 3003–3026.
- Fontana J, Zimab M, Vetvickac V. (2018). Biological markers of oxidative stress in cardiovascular diseases: after so many studies, what do we know? Immunol Invest, 47.
- Franceschi C. (1989). Cell proliferation, cell death and aging. Aging (Milano), 1(1), 3–15.
- Franceschi C, Bonafe M, Valensin S, et al. (2000). Inflamm-aging. An evolutionary perspective on immunosenescence. Ann NY Acad Sci, 908, 244–254.
- Franceschi C, Monti D, Sansoni P, Cossarizza A. (1995). The immunology of exceptional individuals: the lesson of centenarians. Immunol Today, 16(1), 12–16.
- Kirkwood KL, Zhang L, Thiyagarajan R, et al. (2018). Myeloid-derived suppressor cells at the intersection of inflammaging and bone fragility. Immunol Invest, 47.
- Lefer DJ, Granger DN. (2000). Oxidative stress and cardiac disease. Am J Med, 109(4), 315–323.
- Mishto M, Santoro A, Bellavista E, et al. (2003). Immunoproteasomes and immunosenescence. Ageing Res Rev, 2(4), 419–432.
- Molloy MJ, Bouladoux N, Belkaid Y. (2012). Intestinal microbiota: shaping local and systemic immune responses. Semin Immunol, 24(1), 58–66.
- Monteiro R, Azevedo I. (2010). Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm, 2010.
- Olivieri F, Procopio AD, Montgomery RR. (2014). Effect of aging on microRNAs and regulation of pathogen recognition receptors. Curr Opin Immunol, 29, 29–37.
- Salminen A, Huuskonen J, Ojala J, et al. (2008). Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging. Ageing Res Rev, 7(2), 83–105.
- Sawant A, Ponnazhagan S. (2013). Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease. Oncoimmunology, 2(5), e24064.
- Steinkamp HM, Hathaway-Schrader JD, Chavez MB, et al. (2018). Tristetraprolin is required for alveolar bone homeostasis. J Dent Res, 97(8), 946–953.
- Wyss-Coray T, Rogers J. (2012). Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med, 2(1), a006346.